期刊文献+

聚合酶链反应限制性片段长度多态性检测雌激素受体基因型 被引量:3

Estrogen receptor genotype determi ned by polymerase chain reaction-re striction fragment length polymorp hism
下载PDF
导出
摘要 目的建立一种简便、实用、准确的人雌激素受体(ER)基因型的检测方法以利于了解基因对骨量变异的调节。方法采用聚合酶链反应限制性片段长度多态性(PCR-RFLP)来扩增ER基因序列,用限制性内切酶PvuII对223例健康妇女和49例男性的ER基因扩增产物酶切,测定ER基因限制性片段长度多态性(RFLP)。结果汉族妇女ER基因pp、Pp、PP基因型频率分列为0.33、0.47和0.202;男性分别为0.429、0.469和0.102。结论该方法简便、准确、重复性好,适用于常规实验。ER基因(PvuII)多态性分布有一定的种族差异性。 Objective To establish a simple,practical and accurate method for testing estrogen receptor(ER)genotype used in variation for genetic regulation of bone mass.Methods The ER gene sequences were amplified by polymerase chain reaction(PCR),PCR products of223healthy women and 49men were dige sted with PvuII.The genotypes of the restriction fragment length polymo rphism(RFLP)of ER gene were detected.Results The frequency of genotype of ER gene were pp 0.33,Pp 0.47and PP 0.202in wom en and pp 0.429,Pp 0.469,PP0.102in men.Conclusions PCR-RFLP method is a simple and precise technique for obtaining accurate results.It is sutable for routine laboratories.The polymorphism of ER gene(PvuII)there was some difference in differe nt nationalities.
出处 《中国临床康复》 CSCD 2002年第21期3230-3231,共2页 Chinese Journal of Clinical Rehabilitation
基金 国家自然基金资助项目(39970660)
关键词 雌激素受体 基因型 聚合酶链反应 多态性 骨量变异 estrogen receptor genotype polyme rase chain reaction polymorphism
  • 相关文献

参考文献8

  • 1GOSDEN JR,MIDDLEZON PG,ROUT D. Localization of the human estrogen receptor gene to chromosome 6 q24- q27 by in situ hybridization[J].Cytogenet Cell Genet, 1986,43(3):218- 220.
  • 2PONGLIKITOMONGKOL M,GREEN S,CHAMBON P. Genomic organization of the human estrogen receptor geme[J]. EMBO J ,1988,7(11):3385- 3388.
  • 3MORRISON NA,QI JC, TOKITA A, et al. Prediction of bone density from vitamin D receptor alleles[J]. Nature, 1994,367:284- 287.
  • 4KOBAYASHI S, INOVE S, HOSOI T, et al. Association of bone mineral density with polymorphism of the estrogen receptor gene[J]. J Bone Miner Res, 1996, 11:306- 311.
  • 5SAMBROOK J. Molecular cloning: a laboratory manual[M]. 3rd ed. New York: Cold Spring Harbor Laboratory, 1989:931- 958.
  • 6SALAMONE L, WOLF R, BLACK D, et al. Association between bone mineral density and the estrogen receptor genotype in premenopausal women[J]. J Bone Miner Res, 1999,14(suppl 1):SA097.
  • 7KIM SW, KIM CH, CHUNG YE, et al. The association of quantitative ultrasound parameters of the calcaneus with vitamin D receptor gene and estrogen receptor gene polymorphism in Korean postmenopausal women[J]. J Bone Miner Res, 2000,15 (suppl 1):SU 107.
  • 8BORI Z, SPEER G, TAKACS I, et al. Interactive effect of vitamin D and estradiol receptor genotype as a depterminant of bone mineral density[J]. J Bone Miner Res, 1999, 14(suppl 1):SA100.

同被引文献37

  • 1无,章振林,夏维波,李梅,程晓光,谢忠建,刘建民,徐又佳.原发性骨质疏松症诊疗指南(2022)[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(6):573-611. 被引量:161
  • 2柳林,董砚虎,司元国,曲宁.雌激素受体基因多态性与2型糖尿病骨量的关系[J].中国骨质疏松杂志,2004,10(4):466-470. 被引量:3
  • 3[1]Ciovannucci E. Insulin-like growth factor-Ⅰ and binding protein-3 and risk of cancer. Norm Res 1999; 51:334 -41
  • 4[2]Surmacz E. Function of the IGF-Ⅰ receptor in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5(1): 95 - 105
  • 5[3]Mauro L, Bartucci M, Morelli C. IGF-Ⅰ receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction proteinZO-1. J Biol Chem 2001; 276(43): 39892 -7
  • 6[4]Guvakova MA, Surmacz E. Overexpressed IGF-Ⅰ receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 1997; 231 (1): 149 -62
  • 7[5]Dunn SE. Torres JV, Oh JS. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-Ⅰ depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 2001; 61 (4): 1367 - 74
  • 8[6]Takahashi K, Suzuki K. Association of insulin-like growth-factor-Lindu-ced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. Int J Cancer 1993; 55 (3): 453 - 8
  • 9[7]Espinoza F, Anguiano A. The HercepTest assay: another perspective. J Clin Onco 1999; 17(10) :2293 -4
  • 10[8]Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 inmunophenotype and gene amplification. J Clin Onco 2001; 19 (10):2587 -95

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部